ATTAIN-1: Investigating Orforglipron for Obesity Management
Diabetes Insights - Breakthroughs and InnovatorsShow Notes
In this episode, Dr. Sean Wharton (University of Toronto and Wharton Medical Clinic, Canada) and Dr. Nasreen Alfaris (King Fahad Medical City, Riyadh, Saudi Arabia) join host Vivienne Parry to discuss the groundbreaking ATTAIN trial, presented at the EASD 2025 Annual Meeting in Vienna.
The trial tested Orforglipron, the first oral small molecule GLP-1 receptor agonist, showing promising results in weight reduction and cardiometabolic improvements among people living with overweight or obesity.
Beyond the data, the discussion explores what makes Orforglipron different, from its potential to expand access and affordability, to its implications for type 2 diabetes prevention. With obesity now the most common chronic disease worldwide, could this be a pivotal step toward truly scalable care?
More from Diabetes Insights - Breakthroughs and Innovators
How does exercise stimulate glucose uptake in muscle and what can this teach us about treating type 2 diabetes?
Prof. Anette-Gabriele Ziegler, this year’s Claude Bernard Prize Lecture recipient, reflects on her career in type 1 diabetes research and the evolution of our understanding of the disease.
The EASD’s first clinical practice guideline on the assessment and management of diabetes distress in adults living with type 1 or type 2 diabetes has now been published in Diabetologia.
How can people living with diabetes help shape the future of diabetes care?
In this episode, Dr Jeroen van der Velde explores one of the most common questions in lifestyle medicine: does the time of day you exercise make a difference?